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COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially
reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles
(small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects
and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of
respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by
spirometry. GARD of WHO has defined COPD “a preventable and treatable disease”. The integration among general
practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD
person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed
and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting
bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 < 60% predicted and ≥ 2 exacerbations/year, ICS
may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment.
Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and
exhibiting a PaO2≤ 55 mmHg (SO2 < 88%) or PaO2 values between 56 and 59 mmHg (SO2 < 89%) associated with
pulmonary arterial hypertension, cor pulmonale, or edema of the lower limbs or hematocrit > 55%. Respiratory
rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms
and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves
dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual
symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The
pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase
by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic
corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to
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treatment at home hospital admission should be considered. Patients with “severe” or “very severe” COPD who
experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure.
An integrated system is required in the community in order to ensure adequate treatments also outside acute care
hospital settings and rehabilitation centers. This article is being simultaneously published in Sarcoidosis Vasc Diffuse Lung
Dis 2014, 31(Suppl. 1);3-21.
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Respiratory diseases currently represent the second cause
of death worldwide, though they are underestimated. Be-
cause of the increasing life span of general population and
the persisting smoking habit, chronic obstructive pulmon-
ary disease (COPD) is expected, based on the current
trends of incidence, to become the third cause of death
worldwide by 2020.
Symptoms of COPD, cough, phlegm, and dyspnea, are
often overestimated and the diagnosis is made only in
the sixth decade of life, when the patients are already in
the moderate-to-severe stage and lung function is im-
paired. Frequently, the diagnosis is made when the pa-
tient is hospitalized because of an exacerbation, which
points to the inadequacy of the current standards for
diagnosis and treatment.
This document is an update of the COPD guidelines
published in Italy by the National Agency for Regional
Health Services (AGE.NA.S.) and is intended to offer an
instrument for practical and integrated management of
COPD, aiming at appropriateness of diagnosis and therapy.
The document is addressed to pulmonologists and other
specialists working either inside or outside hospitals, gen-
eral practitioners, other health professionals, patient’s asso-
ciations, and institutions at national, regional, or local level.
Figure 1 shows general guidelines for COPD management.
The document has been prepared by a working group
appointed by the three major national respiratory soci-
eties (AIMAR, AIPO e SIMeR) and the Italian Society of
General Medicine (SIMG). Representatives of the Italian
Ministry of Health and AGE.NA.S. were involved as ex-
ternal independent observers to warrant for ethical, so-
cial and solidarity principles.
The reference list of each chapter is meant to be essen-
tial and not exhaustive regarding the information given.Methodological note
Health Information is the spread of any health-related in-
formation, without assessment of the impact that the mes-
sage has on addressees. It can be done by direct verbal
messages, movies, brochures, posters, or other media (e.g.
web) [1,2].
Health Education is a set of general information on be-
havioral norms, knowledge, attitudes, habits and valuesthat contribute to expose to or protect from harm to health.
It applies to both healthy and sick people. It includes gen-
eral norms that can be learnt in different contexts, such as
family, school, society and health organizations [1,2].
Therapeutic Education is a set of educational activities
in favor of specific categories. It is put into action by
transmission of knowledge, training to achieve skills and
promote behavioral changes. It requires that educators
have specific knowledge of science and communication,
with proficiency in the use of specific methodologies and
verification of results [3].
The goal of Health Education is to improve the effi-
cacy of treatments for chronic pathological conditions
through the active and responsible participation of pa-
tient to therapeutic plan. The improvement of life-style
in support of treatments and the participation in the
choice of changes account for a greater efficacy of treat-
ments and psycho-physical personal well-being.
COPD definition and diagnosis
Definition
COPD is a chronic pathological condition of the respiratory
system characterized by persistent and not fully reversible
airflow obstruction, to which variably contribute pathologic
change of bronchi (chronic bronchitis), bronchioles (small
airway disease) and lung parenchyma (pulmonary emphy-
sema). COPD is caused by the inhalation of noxious agents,
mainly tobacco smoke, which cause chronic inflammation
by various mechanisms. Clinical manifestations are chronic
cough and phlegm, dyspnea and reduced exercise tolerance.
Pathophysiology
Chronic airflow obstruction is the results of a combin-
ation of various abnormalities differing for type, site, se-
verity and extent. In a number of patients, perhaps the
majority, the reduced caliber of airways, mainly the more
peripheral ones with a diameter < 2 mm [1,4], due to in-
flammation, mucous hypersecretion and remodeling,
and the destruction of lung parenchyma may cause:
 Static lung hyperinflation, i.e., an increase in the
volume at which lung and chest wall are at static
equilibrium, due to reduction of lung elastic recoil
pressure.
Figure 1 General guidelines for prevention and care of chronic respiratory diseases.
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expiratory lung volume above the static equilibrium
volume, due to increased airflow resistance. In more
severe patients it may be present even at rest; in less
severe ones it occurs when either minute ventilation
is increased, e.g., during exercise, or airflow resistance
is further increased, e.g., during exacerbations.
 Ventilation-Perfusion mismatching.
COPD can cause important systemic effects and be as-
sociated with complications and comorbidities, common
in elderlies or more severe cases. COPD is the common-
est cause of chronic respiratory failure and disability.
Diagnosis
The diagnosis of COPD is based on a history of expos-
ure to risk factors, either associated or non-associated
with respiratory symptoms, and the demonstration of
airflow obstruction by (simple) spirometry and add-
itional pulmonary function tests.
A ratio of 1-s forced expiratory volume (FEV1) to vital
capacity (FEV1/VC) remaining below the limit of normality15–30 min after the inhalation of a bronchodilator (salbu-
tamol 400 μg) is sufficient to confirm the diagnosis. The
fixed ratio FEV1/FVC < 70%, frequently used as a lower
limit of normality yields falsely negative results in subjects
aged < 50 years and falsely positive results in those aged >
50 years [5-7]. Therefore, the use of the 95° percentile of
predicted FEV1/VC for age and sex is recommended. It
must also be noted that the vital capacity measured with a
forced expiratory maneuver (FVC) may be underestimated
compared with that measured with a slow maneuver
(VC). The functional abnormality of COPD can be charac-
terized by comprehensive physiological studies, which
should be included in the diagnostic process in addition to
simple spirometry. These include the measurement of ab-
solute lung volumes, particularly residual volume [8] and
functional residual capacity, and lung diffusion capacity
for carbon monoxide (DLCO) to evaluate the degree of
lung hyperinflation, gas trapping, and the presence of pul-
monary emphysema [9,10].
Spirometry is a necessary investigation to confirm the
diagnosis of COPD and represents, together with symp-
toms, quality of life, frequency and severity of exacerbations,
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evaluate clinical condition and to make choice of the most
appropriate treatment. If the subject is unable to perform
acceptable spirometry maneuvers, the doctor should treat
him/her as “suspected COPD” based on history and clin-
ical data. Persisting or recurrent episodes of cough,
sputum for several consecutive days and respiratory infec-
tions (cold, flu-like syndrome, bronchitis) with slow reso-
lution and, mainly, dyspnea disproportioned to effort or
age are signs that must be reported to the general practi-
tioner. This is in charge of recording the respiratory symp-
toms of his/her patient (also using the respiratory risk
chart for COPD) and referring him/her for appropriate
diagnostic investigations, particularly spirometry and/or
pulmonologist’s visit. General practitioners are also in
charge for active search of new cases, through the use of
questionnaires suitable for case finding among individuals
potentially affected by COPD. The use of an electronic
record carefully updated with patient’s data enables the
general practitioner and the specialist to monitor disease
progression. Scientific societies must be active in pursuing
this goal, while the central and local Institutions mustFigure 2 Proposal of diagnostic procedure and case finding for COPDsensitize the general population. Figure 2 shows the diag-
nostic procedure for COPD.
Integrated hospital and primary care of the
patient with stable COPD
The Global Alliance against Chronic Respiratory Diseases
(GARD) of the World Health Organization (WHO) has
defined COPD “a preventable and treatable disease”;
hence a great responsibility is cast on government and
health local Authorities, on Hospital Chest Physicians, on
primary care Physicians and staff and, last but not least,
on scientific societies.
GARD recommends that National Health Systems
works to get the following goals:
 total tobacco control (as a cause of COPD) and
control of other (less relevant) risk factors;
 health education driven actions toward general
population for primary and secondary prevention;
 COPD screening with simple and affordable means;
 professional education of health staff to risk factors
(primary prevention), to screening procedures (also.
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putting them at risk of developing COPD) and to
optimal and sustainable treatments;
 patient education to self management of COPD;
 a COPD care network of health staff aimed at
integrating the current fragmented ultra-specialistic
knowledges using well known, shared guidelines and
protocols.
Follow up of stable COPD patient
Key points
The management of a person suffering from COPD can
reach high complexity levels during the advanced stages
when reduced gas exchanges, reduced exercise capacity,
increasing breathleness and important cardio-vascular,
metabolic, oncologic and psychiatric comorbidities can
be associated with a severe functional deficit.
This sub-population of patients with advanced COPD,
even if a small proportion of the total population, is re-
sponsible for the highest use of heath system resources,
having a strong impact on NHS. It requires a complex
management, coordinated between specialized and pri-
mary care. The best management can be attained with a
careful integration among chest physician, general prac-
titioner as well as other specialists, whenever required.
For each health professional specific tasks should be
defined, which should be included in diagnostic and
therapeutic pathways, previously designed and shared
for each severity stage of the disease.
Table 1 shows the proposals for the follow up of
COPD, according to different severity stages. Which type
of control, by which health professional and at what time
is carried out are also specified.
Management of COPD in stable state
Key points
COPD is a chronic and complex condition which usually
tends to worsen over time. To control this evolution it is
necessary to quit smoking and eliminate risk factors as
well as to comply with the proper treatment (both
pharmacologic and non-pharmacologic) which should be
continued over time and tailored to the individual per-
son needs, using clinical sings and functional test to step
up the treatment.
Also comorbidities (mainly cardiovascular and meta-
bolic) and complications should lead the choice of the
treatment.
Smoking cessation is the first and most important treat-
ment for coping with COPD. If it is impossible to elimin-
ate any other risk factors, then a strict control of the
characters of life and work environment is mandatory.
General practitioners should record a complete smoking
history and current status of their patients on their data
bases. They are entitled to a minimal advice, which - onthe existing evidences - has been shown effective and
cost-effective.
If a person diagnosed as COPD is not able to quit
smoking with the minimal advice - since smoking cessa-
tion is an essential therapeutic measure for these pa-
tients - then he/she is entitled to a pharmacologic and
behavioural treatment (second level intervention) [1].
To-date nicotine replacement therapy (NRT) in differ-
ent pharmacologic forms (patch, chewing gum, inhaler,
lozanges), varenicline and slow- release bupropion (bu-
propion-SR) are considered first line treatment When
the prescription of one of these drugs is coupled with a
cognitive- behavioural treatment, a statistically signifi-
cant higher percentage is granted of continuous abstin-
ence (see Table 2).
Every Chest Physician should include smoking cessa-
tion therapy in the treatment of the smoker COPD pa-
tient. He/she should also refers the patient to a smoking
cessation clinic whenever necessary [2].
There is an ongoing debate about the use of e-
cigarette in a smoking cessation therapy [3]. Further-
more, encouragement is also necessary for the COPD
patient to live lifestyles able to contrast sedentariness,
overweight and social isolation.
Pharmacotherapy
It has been widely demonstrated that, in COPD patients,
regular pharmacotherapy improves symptoms, lung func-
tion, and exercise tolerance [1-3]. Furthermore, regular
pharmacotherapy can reduce the rate of decay of lung
function [4-7], and decrease the frequency and severity of
exacerbations [8-15] as well as the number and length of
hospitalizations [14-20].
The main goal of the maintenance pharmacotherapy
of COPD is bronchodilation. Inhaled long-acting bron-
chodilators are the first-line treatment for stable COPD
[LABA (long-acting beta2 agonists): formoterol, salme-
terol, indacaterol. LAMA (long-acting muscarinic anti-
agonists): tiotropium, glycopyrronium, aclidinium].
Recommendations
The prescription and maintenance of pharmacotherapy
needs:
1. The confirmation of the diagnosis of COPD having
ascertained the presence of risk factors, respiratory
symptoms, and spirometric evidence of airflow
obstruction.
2. An active and personalized smoking cessation
program.
3. The strong recommendation for a healthier lifestyle:
 healthy nutrition program, and weight control;
 regular physical activity;
 social life.
Table 1 Planning COPD monitoring
Planned actions Monitoring chronic bronchitis
(without flow limitation) or
mild COPD (FEV1/CV < LLN
and FEV1 > 80%) without
symptoms
Monitoring COPD with FEV1 < 80%
and/or exercise dyspnea and/or
comorbidities
Monitoring COPD with FEV1 < 60%
and/or exercise dyspnea and/or
frequent exacerbations and/or
comorbidities
Monitoring COPD with FEV1 < 50%
with respiratory insufficiency and
comorbidity**
Timing Every other year Every year Every year Every year
Smoking cessation, if a smoker Every physician/nurse or
smoking cessation clinic
Every physician/nurse or smoking
cessation clinic
Every physician/nurse or smoking
cessation clinic
Every physician/nurse or smoking
cessation clinic
Clinical check (including Body
Mass Index, questionnaires
and assessment of risk factors)
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Pulsoximetry Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Flow-volume curve Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physician consultation Chest physician Chest physician Chest physician Chest physician
Full spirometry Respiratory function unit* Respiratory function unit Respiratory function unit Respiratory function unit
Diffusion test (DLCO) Respiratory function unit* Respiratory function unit* Respiratory function unit
Chest-X-ray* Radiology Radiology Radiology Radiology
EKG* Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
Chest physicians and general
practitioner
EKG cardiac ultrasound Specialized unit Specialized unit Specialized unit
Blood gas analysis (BGA) Respiratory function unit Respiratory function unit
6-min walking test Respiratory function unit Respiratory function unit Respiratory function unit
Nocturnal pulsoximetry* Respiratory function unit Respiratory function unit Respiratory function unit
Other consultation and/or tests* Other consultation and/ or tests* Other consultation and/ or tests* Other consultation and/ or tests*
General practitioners are in charge of
chronic treatment monitoring: Every six
months he/she checks the clinical
situation in own clinic. He/she carries
out a pulsoximetry at each
exacerbation and the following
2 months. Refers the patient to a
consultation in case of persistent
worsening
General practitioners are in charge
of chronic treatment monitoring:
Every three months he/she checks
the clinical situation in own clinic.
Refers the patient to a consultation
in case of exacerbation. Chest
physician has in charge the patient
until the recovery of the steady
state
General practitioners are in charge of
chronic treatment monitoring. Every
two months he/she checks the
clinical situation in own clinic. Quickly
refers the patient to a consultation in
case of exacerbation or complaint
of new symptoms/signs. Chest
physician has in charge the patient
until the recovery of the steady
state and monitors the comorbidities,
using the proper referrals



















Table 2 Smoking cessation therapy (Modified from MC
Fiore, 2008)






Minimal advice (<3 min) 1.3 (1.01-1.06) 13.4 (10.9-16.1)
Counseling 3–10 min 1.6 (1.2-2.0) 16.0 (12.8-19.2)
Counseling > 10 min 2.3 (2.0-2.7) 22.1 (19.4-24.7)
Pharmacologic therapy
Placebo 1.0 13.8
Varenicline 3.1 33.2 (28.9-37.8)
Nicotine replacement therapy (NRT)
Patch (6–14 weeks) 1.9 (1.7-2.2) 23.4 (21.3-25.8)
Chewing gum (6–14 weeks) 1.5 (1.2-1.7) 19.0 (16.5- 21.9)
Inhaler 2.1 (1.5-2.9) 24.8 (19.1-31.6)
SR Bupropion 2.0 (1.8-2.2) 24.2 (22.1-26.4)
Bettoncelli et al. Multidisciplinary Respiratory Medicine 2014, 9:25 Page 7 of 16
http://www.mrmjournal.com/content/9/1/254. Any therapeutic program must be tailored to the
characteristics of the individual patient with COPD
taking into account the severity of the overall
clinical status on the basis of symptoms, lung
function, complications, comorbidities, and, when
possible, the phenotype [21].
5. In symptomatic patients with a confirmed diagnosis
of COPD, dyspnea ≥mMRC stage 1, and with pre-
bronchodilator FEV1 ≥ 80% predicted [22] the caring
physicians may consider treatment with
bronchodilators [23].
6. Regular treatment with inhaled long-acting
bronchodilators is recommended in symptomatic
patients with a confirmed diagnosis of COPD and
pre-bronchodilator FEV1 < 80% predicted [16,24-33].
Two clinical studies showed a better protection to ex-
acerbations for tiotropium compared to LABA although
both categories (LABA and LAMA) provided an effective
bronchodilation [14-16]. Furthermore, a recent clinical
study on a large population of patients has documented
the clinical safety of tiotropium for the available doses and
inhalers [17].
At any control visit, the followings should be evaluated:
 the adherence to the maintenance therapy;
 the changes in symptoms, and in particular in
dyspnea and exercise tolerance;
 the changes in lung function: not only for FEV1, but
also lung volumes and, when needed, DLCO;
 the use of rescue medications;
 the rate and severity of exacerbations; the frequency of hospitalizations and the length of
stay;
 the adverse events.
If the patient or/and the caring physician are not satis-
fied with the results of the prescribed long-acting bron-
chodilator monotherapy, one of the followings should be
considered:
 an increase in the dose of the bronchodilator
according to its pharmacologic characteristics [26-29];
 the addition of a second long-acting bronchodilator
with a different mechanism of action [34-44];
 the addition of inhaled corticosteroid (ICS), in
patients with frequent exacerbations [8,9,11,39-41].7 In patients with COPD, who:
 remain symptomatic despite the regular use of
long acting bronchodilator(s),
 present a pre-bronchodilator FEV1 < 60% predicted
[9], and
 suffer ≥ 2 exacerbations/year [45]the addition of ICS to LABA may be considereda. The
use of a single inhaler fix dose combination LABA + ICS
may improve the adherence to treatment [8,9,11,46-49].
8 In those patients, the “triple therapy”, i.e. LAMA +
LABA + ICS, can improve lung function and quality
of life, and reduce the number of hospitalizations
[16,48,49].
9 In COPD patients with:
 symptoms of chronic bronchitis,
 pre-bronchodilator FEV1 < 50% predicted, and
 frequent exacerbations, i.e. ≥ 2/year,the addition of a phosphodiesterase-4 inhibitor (roflumi-
last) on top of regular treatment with long-acting bron-
chodilator(s) can further improve lung function and
reduce the exacerbation rate [50-54].
Conventionally, the airflow obstruction is defined as se-
vere in COPD patients with FEV1 < 50% predicted and
very severe in those with FEV1 < 30% predicted. This clas-
sification is the result of an “expert agreement” and is not
either based on the evidence from prospective studies or
somehow correlated to the severity of the patient’s overall
clinical status. However, for operational and communica-
tion purposes, it may be useful to suggest a conventional
agreement on three stages of the severity of airflow ob-
struction, in patients with a FEV1/VC < 95° predicted [40]:
 mild: FEV1 ≥ 80% predicted
 moderate: FEV1 < 80% and ≥ 50% predicted
 severe: FEV1 < 50% predictedb
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into account non only the lung function abnormalities
but also some other clinical aspects relevant for the
overall patient evaluation: BODE [55-57], DOSE [58],
ADO [59]. However their use in the clinical settings to
assess the status and the progression of COPD as well as
the effects of therapeutic strategies is limited [60].
Oxygen and non-pharmacological therapy
Severe COPD is commonly associated with respiratory
failure, which is characterized by arterial hypoxemia
(PaO2/FiO2 < 300 mmHg). Evidence suggests that chronic
hypoxemia with PaO2values less than 55–60 mmHg, if un-
treated by supplemental oxygen, leads to an increase in
mortality [1].
In such cases, a continuative long term oxygen therapy
(LTOT) is required, for a duration of at least 15 hours
[1] or, better, 18–24 hours a day [2]. Oxygen administra-
tion should be continued overnight at an average flow
rate of 1–2 L/min. Oxygen flow rate should be tailored
to maintain the PaO2 value and oxygen saturation
(SaO2%) above 60 mmHg and 92%, respectively.
In hypercapnic patients oxygen supplementation must
be provided at a low flow rate in order to avoid increases
of carbon dioxide retention and respiratory acidosis
(pH < 7.36) [3].
According to both national and international guide-
lines [4,5], LTOT is indicated in stable patients, at rest
while receiving the best possible treatment, and exhibit-
ing a PaO2 ≤ 55 mmHg or PaO2 values between 56 and
59 mmHg associated with pulmonary arterial hyperten-
sion, cor pulmonale, o edema of the lower limbs or
hematocrit > 55% in consecutive arterial blood gas ana-
lyses obtained at an interval of at least fifteen days over
a two months period [5,6].
Efficacy of oxygen at the prescribed flow rate and per-
sistence of the indication to LTOT should be verified at
intervals of 3 to 12 months after prescription [7] and, on
regular basis, at least once a year or whenever required
by clinical changes [5].
Patients with COPD and chronic respiratory failure
having frequent exacerbations requiring hospitalization,
and hypercapnia (PaCO2 > 45 mmHg) may benefit from
non-invasive ventilation (NIV) treatment [8], initiated
after evaluation by competent specialists.
In selected patients, lung function improvement
throughout surgical procedures such as bullectomy or
lung volume reduction either by resection of emphyse-
matous lung parenchyma or insertion of unidirectional
endobronchial valves aimed to desufflate lung paren-
chyma or other bronchoscopic procedures still under
evaluation should be considered [9]. These procedures
should be reserved for thoroughly selected patients and
performed in reference centers.COPD patients aged less than 65 years, with severe
lung function and clinical impairment, FEV1 value less
than 20% of predicted, a history of frequent hospitaliza-
tions for exacerbation and requiring LTOT, should be re-
ferred for lung transplant evaluation, which has been
proven to have a positive impact on outcomes such as
lung function, exercise performance and quality of life,
whereas its impact on survival remains unproven [10,11].
Rehabilitation
Key points
Respiratory rehabilitation (RR) is defined as “a global
and evidence-based multidisciplinary intervention, aimed
at patients with chronic respiratory disease in all stages of
severity who report symptoms and limitation of their daily
activity.
If integrated in a tailored treatment for COPD, RR has
the purpose of controlling symptoms, optimizing the
performance status, improving participation and redu-
cing healthcare costs by achieving clinical improvement
and/or stability.
Outcomes
Respiratory rehabilitation (RR) improves dyspnea, exer-
cise performance and quality of life in COPD patients.
There is minor evidence for other outcomes such as pre-
vention of complications and exacerbations, slowing of
disease progression and survival. In addition, RR seems
effective in cutting healthcare costs through a reduction
of emergency visits and hospitalization length. In con-
trast, RR has no impact on FEV1 decline and progressive
lung function deterioration in COPD.
Patient selection
Accurate patient selection and program personalization
are of major importance for the success of RR.
Contraindications
Age and disease severity do not represent contraindica-
tions to RR. Current smoking is not a contraindication
provided that the rehabilitation program includes ses-
sions aimed at smoking cessation. Main contraindica-
tions are summarized in Table 3.
Structure of the rehabilitation program
A tailored rehabilitation program comprehends both
useful and mandatory activities in variable combination
depending on the initial assessment, and grouped in es-
sential or fundamental and ancillary or complementary
(Table 4).
Assessment of results
Outcomes of RR are assessed with regard to every aspect
of COPD. Therefore assessment of improvement in lung
Table 3 Main contraindications to respiratory rehabilitation
Absolute contraindications Other contraindications
Unwillingness to participate in the program Linguistic barriers
Poor adherence to the program Cognitive impairment
Socio-economic barriers
Logistic barriers
(e.g. distance from hospital)
Table 5 Indicators and outcomes
Indicators Outcomes
Lung function assessment(m) Improvement of exercise tolerance
Exercise tolerance assessment(m) Improvement of symptoms (dyspnea)
Dyspnea assessment(m) Improvement of the quality of
life (QoL)
Muscular assessment(c) Increase in survival rates
Psychological assessment(c) Control and rationalization of costs
Nutritional assessment(c)
Quality of life assessment(m)
(m)Mandatory; (c)Complementary.
Table 6 Measures that may be adopted in preventing
COPD exacerbations
Measure Efficacy
Influenza vaccination Documented efficacy
Long term tiotropium administration Documented efficacy
Long term LABA administration Documented efficacy
LABA + inhaled corticosteroid administration Documented efficacy
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currently used. The functional assessment is of major
importance at the initial evaluation to customize the RR
program. Indicators and outcomes are shown in Table 5.
Exacerbations
Key points
Patients with COPD experience exacerbations during
the natural course of their disease condition. Frequency
and severity of exacerbations are among the factors that
determine the prognosis of COPD.
COPD exacerbations are the leading cause of medical
consultations, hospitalizations and death among patients
with greater functional compromise. Among COPD pa-
tients, exacerbations may temporarily induce conditions
of relevant physical inability, even after hospital discharge.
A recent study indicates that susceptibility to exacer-
bations seems to remain constant over time, both among
frequent exacerbators (≥2 exacerbations per year), and
infrequent exacerbators (<2 events per year), irrespective
of underlying disease severity ([88-90]. Patients with
COPD who experience a greater number of exacerba-
tions may be at higher risk of a more rapid decline in re-
spiratory function [4,6].
It is of paramount importance to prevent exacerba-
tions and to treat events promptly at symptom onset, in
order to reduce the impact of exacerbations on health
status and patient quality of life.
Up to 70% of the overall costs of COPD management
may be attributable to exacerbations, particularly to
those that require hospitalization.
Acute exacerbations of COPD (AECOPD) are defined
as an acute worsening of usual symptoms in a patient
with COPD (dyspnea, cough and sputum production),
over and beyond normal daily variability that requiresTable 4 Classification of rehabilitation activities
Fundamental activities Complementary activities
Optimization of pharmacotherapy Respiratory muscle training
Training of upper and lower limbs Chest physiotherapy
Health education Nutritional support
Therapeutic education
Psychologic and psychosocial supporttreatment modification, i.e. a course of systemic steroids
and/or antibiotics [1].
During a worsening of symptoms it is important to
distinguish true exacerbations from symptoms due to
other conditions such as pulmonary embolism [7,8],
congestive heart failure, pneumothorax, pneumonia, cos-
tal or vertebral fracture, inappropriate drug use (seda-
tives, narcotics and betablockers). The most common
causes of exacerbations are viral and/or bronchial infec-
tions of the tracheobronchial tree [9].
Preventing exacerbations
Measures that may be adopted for preventing exacerba-
tions and their efficacy are summarized in Table 6.
Treatment of exacerbations
In the outpatient management of exacerbations, the first
step is the additional use of short acting bronchodilators
(SABA or SAMA) [10], by increasing the dose or modi-
fying the route of administration of drugs used during
the stable phase.
There is evidence regarding the efficacy of administer-
ing systemic corticosteroids during an exacerbation. It isLAMA + LABA + ICS Documented efficacy
Continuation of systemic steroid therapy
for a brief period after AECOPD
Documented efficacy
Respiratory rehabilitation Documented efficacy
Smoking cessation Documented efficacy
Polysaccharide antipneumococcal vaccination Controversial efficacy
Antioxidant-mucoactive drugs Controversial efficacy
Bacterial lysate Possible efficacy
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http://www.mrmjournal.com/content/9/1/25advisable not to exceed the dose of 30–40 mg a day of
prednisone for 7–14 days [11-13].
Antibiotics are particularly recommended in exacerba-
tions where both increase in sputum volume and sputum
purulence are present [14-18]. There is no demonstration
that for single drugs parenteral administration is superior
to the oral route.
Notwithstanding prompt institution of treatment, some
patients do not respond to outpatient management and
may satisfy one or more criteria for hospital admission
(Table 7).
Strict adherence to these criteria is of extreme import-
ance in order to reduce inappropriate hospital admission
for COPD exacerbations. In general terms, the presence
of comorbidities does not alter the treatment scheme for
COPD exacerbations. Comorbidities should be treated
independently. Hospital admission is justified particu-
larly when respiratory failure develops or worsens as
testified by blood gas analysis. SpO2 values below 92%
suggest presence of hypoxemia.
In exacerbations with overt respiratory failure (PaO2/
FiO2 ≤ 300 mmHg) oxygen administration is necessary
to maintain pulseoxymetry (SpO2) ≥ 93%. Values ≥ 88%
may be considered acceptable when high flow oxygen
may precipitate hypercapnia [19-21].
In the presence of ventilatory failure (PaCO2 > 45 mmHg)
and/or respiratory failure (PaO2/FiO2 ≤ 300 mmHg and
PaCO2 > 45 mmHg) with respiratory acidosis (pH ≤ 7.35),
non invasive ventilation should be considered as it has
been shown to reduce mortality and the need for endo-
tracheal intubation [19-22].
Integrated hospital-community management of
patients with severe COPD
Hospital management of the acute phase
Patients with “severe” or “very severe” COPD who experi-
ence exacerbations should be hospitalized. Based on the
severity of acute respiratory failure (ARF) [1-2] treatmentTable 7 Criteria for appropriate hospital admission for
COPD exacerbations
• Inadequate or failed response to outpatient treatment
• Presence of high risk comorbidity (pneumonia, arrhythmia, congestive
heart failure, diabetes, liver or renal failure) or very elderly patients
• Past history of frequent exacerbations
• Significant increase in dyspnea and/or onset of new signs
(cyanosis, peripheral edema, arrythmias)
• Significant worsening in hypoxemia
• Worsening in hypercapnia/respiratory acidosis (not detectable at the
patient bedside)
• Mental status alterations
• Lack of or unreliable family assistance
• Diagnostic uncertaintyshould be carried out in respiratory units with different in-
tensity of management capacity (Monitoring Unit, Re-
spiratory Intermediate Care Unit, Respiratory Intensive
Care Unit) [3-5]. When ARF is associated with multiple
organ failure the patient should be admitted to an Inten-
sive Care Unit [4,5]. At discharge, collaboration between
hospital based specialists and general practitioner allows
continuing assistance with the use of targeted organizing
models.
The hospital discharge note is the first tool to guaran-
tee continuing home assistance, as it should include in-
dications on the severity of COPD, degree of functional
compromise as assessed by relevant lung function pa-
rameters, presence and severity of comorbidity, use of
inhaled therapy, and clinical follow up. It should also in-
dicate whether the patient is an active smoker, and set a
treatment program to favour quitting.Home care pathway
In the community, an integrated system is required in
order to ensure adequate levels of assistance outside acute
care hospital settings and rehabilitation centers [6-8]. This
may be obtained through shared computer systems for the
management of patients and the employment of a health
team that includes - in addition to a pulmonologist and
the general practitioner - other health professionals
(Table 8). All professionals involved should be organized
and integrated into a respiratory network evenly distrib-
uted throughout the community. The team should guar-
antee telematic monitoring, a second opinion service
active twenty four hours a day, home pulmonologist
examination, and prompt hospitalization in the presence
of foreseeable clinical critical conditions.Palliative and end of life care in COPD
Palliative care should be integrated within the treatment
plan for patients with COPD [9-11] and be initiated
when symptoms such as dyspnea, pain, depression, anx-
iety and constipation are not completely controlled by
standard pharmacological treatment.
The term palliation encompasses interventions aimed
at preventing and relieving patient suffering through
symptom control, so as to stabilize or improve quality of
life.Table 8 Health professionals involved in home
management of patients with respiratory failure
• Reference physician for Home Care
• Trained nurse
• Respiratory therapist for rehabilitation
• Psychologist
• Dietician/nutritional counsellor
Table 10 Critical aspects in teleassistance
• Possible loss of direct patient-physician contact
• Personal data
• Difficulties in accessing the assistance web
• Poor interactivity between computer systems
• Paucity of uniform political strategies across the nation
• Paucity of definitive data on the efficacy of the system
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http://www.mrmjournal.com/content/9/1/25The concept of end of life assistance is instead re-
served to the terminal phase of the disease and implies
“comfort” or support measures for both the sick person,
and for his/her family members [10].
Palliation and end of life care require multidisciplinary
involvement of physicians, nurses, physiotherapists, psy-
chologists, social workers, home care providers, and
clericals when requested [11].• Absence of specific legislation on the aspects of security regarding
both the patient and the prescribing physicianTelemedicine and teleassistance
The management of chronic conditions and continuing
assistance may be greatly improved through the applica-
tion of innovative technologies, among which telemedi-
cine, teleassistance and more in general Information and
Communication Technology (ICT). Application of these
systems is particularly useful in guaranteeing a network-
based operative frame for taking charge of patients with
chronic disease. The National Program for Research and
Formation in Telemedicine [12] indicates telemedicine
as “a particular means of providing health assistance
from community-based institutions, that allows inte-
grated delivery of diagnostic and management medical
measures, overcoming the barriers associated with terri-
torial distribution of different competences, bridging
the gap between subscribers and the experts, and redu-
cing temporal fragmentation of interventions on single
patients”.
The use of telemedicine tools is aimed at reaching a
greater degree of interaction between the community
and reference clinical centers, reducing the need for
transferral of frail and often elderly patients. Telemedi-
cine guarantees contacts between centres with differ-
ent clinical expertise, dialogue through equipment
present in the patient’s home, assistance to remote or
isolated areas, emergency interventions, solidarity to
low income countries. The Italian National Health Plan
for the years 2011–2013 [13] underlines the need for
telemedicine implementation in order to guarantee
access to specific health assistance. Tables 9 and 10
respectively summarize the aims and critical issues of
teleassistance.Table 9 Aims of teleassistance
• Improve patient quality of life
• Improve family member’s quality of life
• Increase the degree of patients safety at home
• Avoid hospitalizations
• Reduce outpatient general practitioner consultations
• Reduce outpatient respiratory specialist consultation
• Reduce need for patient transferral, and associated costsThe role of institutions
In consideration of organisational and institutional com-
petences, it is helpful that central institutions (which are
in charge) do ensure the training of an appropriate num-
ber of Specialists for the needs of assistance. Further-
more, in consideration of the epidemiological data, the
Ministry of Health and Regional Health Institutions do
insert a specific section for acute and chronic respiratory
diseases in their planning, namely for COPD; the Re-
gions and Local Health Units do their best for the
reinforcement and homogeneity of the network for lung
function assessment. At the same time it is helpful that
in the whole country the distribution of Pulmonary Divi-
sions with Units of Respiratory Intensive Care or Inter-
mediate Intensive Units or Respiratory Monitoring Units
is organized according to precise criteria of inhabitants
number and/or extension of the area. In addition it should
be realized, at least at regional level, a telemonitoring ser-
vice active twenty four hours a day through a call center,
which can telematically receive all the parameters that
should be monitored (pneumological teleassistance), and
at the same time can guarantee a comprehensive health-
care support to the patient with respiratory failure. Fur-
thermore, it is helpful that in every region some
rehabilitation centers for post-acute patients can be found,
with a ratio of day-beds suitable for population; at the
same time, centers of outpatient respiratory rehabilitation
can be active in every Local Health Unit and able to give
the care needed by the patient in the steady phase of the
disease, with costs under control. Last, it is important the
Ministry of Health includes the therapeutical education
even in the LEAs (Essential Levels of Healthcare) of
COPD patient.Endnotes
aEMA–AIFA for salmeterol 50/fluticasone 500 mcg
bid “symptomatic treatment of COPD patients with
FEV1 < 60% predicted (pre-bronchodilatar) and a clin-
ical history of frequent exacerbations, with important
symptoms notwithstanding the regular therapy with
bronchodilators”.
bIt must be considered as pre-bronchodilator.
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